Directorate Change

RNS Number : 1616H
Advanced Medical Solutions Grp PLC
02 August 2021

2 August 2021

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)


            Directorate Change


            Douglas Le Fort Appointed as Independent Non-Executive Director


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, is pleased to announce that, as the next step in its communicated plan to refresh the Non-Executive Directors on the Board, Douglas Le Fort has today been appointed as an Independent Non-Executive Director.


Douglas is a seasoned veteran in the medical and life science industry, with more than 20 years of senior executive leadership. He has expertise in business strategy, including commercial business execution, operational management and M&A. He is currently an Operating Partner for Revival Healthcare Capital Partners, an investor in medical device and diagnostics businesses, as well as a Non-Executive Director at Trio Healthcare, a manufacturer of ostomy products. Most recently, he was CEO of MedTrade Products, a woundcare products business and prior to that served in various senior executive roles at ConvaTec Group plc, including five years on the Executive Committee for the Group. At ConvaTec he was Senior Vice President for Corporate Development, and prior to that Vice President and General Manager with P&L responsibility for the global Ostomy business. He has an MBA from Henley Management College and is a Chartered Management Accountant.


Peter Allen, Chairman of AMS, said: “I am very pleased to welcome Douglas to the Board of AMS, who brings with him significant commercial experience, particularly during his time at ConvaTec, as well as sector expertise. He will be an extremely valuable addition to our Board as AMS looks to grow.


Douglas Le Fort commented: “I have been watching AMS’s progress closely during my career and am very excited to be joining the team at such a high-quality Company. Alongside the rest of the Board, my focus will be on supporting AMS’s growth strategy and providing strategic advice as the business builds on its position in the UK and internationally.”


Douglas will immediately join the Audit, Nomination and Remuneration Committees. The composition of each of the Board Committees from 2 August 2021 is therefore confirmed as follows:


Board Committee


Audit Committee

Grahame Cook (Chairman)

Penny Freer

Douglas Le Fort

Nomination Committee

Peter Allen (Chairman)

Grahame Cook

Penny Freer

Douglas Le Fort

Chris Meredith

Remuneration Committee

Penny Freer (Chairman)

Peter Allen

Grahame Cook

Douglas Le Fort

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:


Douglas William Frederick Le Fort (age 55) holds or has held directorships and partnerships in the five years preceding his appointment at AMS as follows:


Current Directorships

Previous Directorships

Trio Healthcare Holdings Ltd

MedTrade Products Ltd

Wolfpack Consulting Ltd


Mr Le Fort was a Director of Freehand Surgical plc in 2010 when it, and its subsidiary Prosurgics Limited, was put into administration. Mr Le Fort had previously been a Director of Prosurgics Limited which had been acquired by Freehand Surgical plc. Freehand Surgical plc was subsequently acquired by Freehand 2010 Limited by way of a pre-pack sale. Mr Le Fort was a Director of Freehand 2010 Limited at the time of it acquiring Freehand Surgical plc.


No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.


-End –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Matthew Cole

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


About Advanced Medical Solutions Group plc


AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.


AMS’s products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.